A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine

NCT03718468 | Completed Phase 3

• 1 other identifier: CT-QV-31
• Study Type: interventional
• Target: 842
• Locations: 1 country
• Sites: 4

Brief Summary

This study aims to demonstrate the immunogenic efficacy of GC FLU Quadrivalent Pre-filled Syringe inj. (GC FLU), a quadrivalent influenza virus vaccine, is non-inferior to the active control, Fluarix Tetra. This study is designed to be a randomized, open-labelled, active-controlled, parallel, phase III study recruiting subjects from multiple study sites. Approximately 840 eligible subjects are planned to enroll in order to obtain 800 evaluable (= per-protocol) subjects. Subjects will be randomized and assigned to GC FLU or Fluarix Tetra (active control, AC) group in 1:1 ratio.

Conditions

Influenza

Outcome Measures

Primary Outcomes (2)

• The Geometric Mean Titer (GMT) Ratio

  The non-inferior immunogenicity of GC FLU compared to active control in terms of HAI titers against each virus strain at 21 days after the vaccination.

  21 days after the vaccination

• The Seroconversion Rate

  The non-inferior immunogenicity of GC FLU compared to active control in terms of HAI titers against each virus strain at 21 days after the vaccination.

  21 days after the vaccination

Study Arms (2)

GC Flu Quadrivalent

EXPERIMENTAL

Biological: GC FLU Quadrivalent

Fluarix tetra

ACTIVE COMPARATOR

Biological: Fluarix Tetra

Interventions

GC FLU Quadrivalent BIOLOGICAL

A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.

GC Flu Quadrivalent

Fluarix Tetra BIOLOGICAL

A single dose administration of Fluarix Tetra will be through intramuscular injection.

Fluarix tetra

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Provision of signed and dated informed consent form
• Either gender, aged 20 to 50 years old (inclusive)
• Willing and able to comply with all the required study visits and follow-up defined by this protocol
• Female subject with childbearing potential or male subject with female spouse/partner with childbearing potential must agree to use highly effective contraceptives from 15 days prior to vaccination until 60 days after vaccination. At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:
• Established use of oral, injected or implanted hormonal methods of contraception
• Placement of an intrauterine device (IUD) or intrauterine system (IUS)
• Barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

You may not qualify if:

• With previous known or potential exposure to influenza virus within 12 weeks prior to vaccination
• Received seasonal influenza vaccine (registered or investigational) within 24 weeks prior to vaccination
• Received any vaccine other than seasonal influenza vaccine within 6 weeks prior to vaccination
• Received other investigational products (including medications and vaccines) within 6 weeks prior to vaccination
• Administered immunoglobulins and/or other blood products within the 12 weeks prior to vaccination
• Known or suspected hypersensitivity to any component of vaccines (including egg proteins); or history of allergy to consumption of eggs
• History of inflammatory or degenerative neurological disease (e.g., Guillain-Barre syndrome)
• With confirmed or suspected immunosuppressive or immunodeficient condition (e.g. HIV infection), or received \> 14 days of systemic steroid with equivalent dosage equal or over to 0.5 mg/kg/day prednisolone or other immune-modifying agents within 24 weeks prior to vaccination
• Positive in HIV, HBsAg, or HCV test
• With fever (defined as body temperature equal or over to 38 °C by any method) on the day of vaccination
• With ongoing acute diseases or within the past 2 years serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the subject
• Female subject who is lactating or has positive serum or urine pregnancy test at screening or vaccination

Sponsors & Collaborators

• Medigen Vaccine Biologics Corp.: lead

Study Sites (4)

National Taiwan University Hospital

Taipei, Taiwan

Location

Taipei Municipal Wan Fang Hospital

Taipei, Taiwan

Location

Tri-Service General Hospital

Taipei, Taiwan

Location

Linkou Chang Gung Memorial Hospital

Taoyuan District, Taiwan

Location

MeSH Terms

Conditions

Influenza, Human

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Study Officials

• Szu-Min Hsieh, MD

  National Taiwan University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 22, 2018
• First Posted: October 24, 2018
• Study Start: October 30, 2018
• Primary Completion: July 3, 2019
• Study Completion: July 3, 2019
• Last Updated: August 14, 2019

Record last verified: 2019-08

Locations

TW (4)